2 models fit BellRing Brands Inc. Common Stock and they disagree: 0 of 2 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Bronze40
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionBellRing Brands Inc. Common Stock (BRBR)
Fair value (2 models)
$30.79
ACCE price target
$11.00
Rating
Undervalued
Horizon
12 months
Fair value published on 20 Oct 2026, 14:06 CEST; previously $24.54 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 14:06 CEST.
Price used: $9.55 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
69.0% below
+222.4% to fair value
ACCE score
60
out of 100
Analysts
60% buy
15 covering
P/E
6.7x
forward 7.2x
1-year return
-71.4%
Dividend yield
0.00%
BellRing Brands Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
BellRing Brands makes Premier Protein shakes and bars, along with Dymatize sports nutrition powders and the Joint Juice line, selling mostly through mass retail and e-commerce in the US. Its edge is brand scale in ready-to-drink protein, where Premier has built a large share of the high-protein shake category against much bigger food companies. Revenue is growing modestly at 4.2%, but the business converts that growth into unusually high returns, with ROE at 61.5% and an 11.5% operating margin, helped by a lean balance sheet that has been used for buybacks. The stock trades at about 6x trailing and forward earnings, a steep discount that reflects investor doubt about how durable protein demand is once competitors and private label push harder on price. The question for a deeper look is whether volume holds as the category matures, and whether the low multiple already prices in a sustained slowdown.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
high
Margin compression vs earnings
Quarter-on-quarter revenue fell 4.7% and net margin is only 7.3%, while earnings growth of 81.3% rests on a thin base. Earnings momentum may not hold if sales keep sliding.
moderate
Elevated short interest
Short interest stands at 12.1% of float, which signals meaningful bearish positioning against the stock and can add volatility around any negative news.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last twelve months reached $256M, a strong cash base relative to the company's size.
Trailing earnings multiple of 6.8x sits far below the sector median forward P/E of 18.3x, suggesting the shares are priced cheaply.
Why it could disappoint
Revenue grew only 4.2% year over year, well below the 18.6% annual average of the past five years.
The latest earnings per share missed expectations by 18.9%, with 0.30 reported against 0.37 forecast.
Negative equity, with debt to equity at -2.45, leaves the balance sheet thin and is a key risk on file.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 17, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where BRBR's valuation models land
Price
$9.55
Model fair value
$30.79
Model range
$24.83 to $35.89
Fair value $30.79
Price $9.55
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores